US Edition
Scientists Use AI to Create Protein that Kills E. Coli
GLOBAL, JUL 6 – Isomorphic Labs aims to improve drug development success rates beyond the typical 10% by using AI to design medicines faster and more accurately, with clinical trials imminent.
- Isomorphic Labs, led by President Colin Murdoch, is preparing to start human clinical trials for AI-designed cancer drugs in 2025 in London.
- This milestone follows Isomorphic's use of AlphaFold technology and a $600 million funding round led by Thrive Capital in April 2025, fueling faster and cheaper drug design.
- Murdoch explained researchers now can input a disease and click a button to receive custom drug designs, accelerating development and improving success rates over traditional methods.
- "We're getting very close," Murdoch said in Paris, adding the next step is clinical trials to start putting AI-designed drugs into human beings.
- If successful, Isomorphic's AI-driven model could reduce drug development costs, increase precision, and transform patient care by addressing unmet medical needs rapidly.
23 Articles
23 Articles
Scientists use AI to create protein that kills E. coli
In the last year, there has been a surge in proteins developed by AI that will eventually be used in the treatment of everything from snakebites to cancer. What would normally take decades for a scientist to create—a custom-made protein for a particular disease—can now be done in seconds.
Google’s AI drug company says human trials are ‘very close’
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. In an interview with Fortune on July 6, Colin Murdoch, Isomorphic Labs’ president and Google DeepMind’s chief business officer, shared that the company is currently gearing up to start human trials. This milestone will mark the first time that Google DeepMind’s breakthrough A…
Isomorphic Labs, Google-backed, to launch human trials for AI-designed drugs
Alphabet’s drug discovery arm, Isomorphic Labs, is preparing to enter a new chapter in its ambitious efforts to reshape medicine through artificial intelligence, with its first human clinical trials now on the horizon. Colin Murdoch, the company’s president and also Google DeepMind’s chief business officer, confirmed to Fortune that trials for AI-designed drugs could begin in the near future. “We’re staffing up now. We’re getting very close,” he…
Google DeepMind has grand ambitions to 'cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet’s drug discovery arm is getting ready to start testing its AI-designed drugs in humans, Google DeepMind's chief business officer, told Fortune.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
